Abstract

Objective. To determine if primary circulating prostate cells (CPCs) are found in all men with prostate cancer. Methods and Patients. A prospective study, to analyze all men with an elevated PSA between 4.0 and 10.0 ng/mL undergoing initial biopsy. Primary CPCs were obtained by differential gel centrifugation and detected using standard immunocytochemistry using anti-PSA; positive samples underwent a second process with anti-P504S. A malignant primary CPC was defined as PSA (+) P504S (+) and a test positive if 1 cell/4 mL was detected. Biopsy results were registered as cancer/no-cancer, number of cores positive, and percent infiltration of the cores. Results. 328/1123 (29.2%) of the study population had prostate cancer diagnosed on initial biopsy, and 42/328 (12.8%) were negative for primary CPCs. CPC negative men were significantly older, and had lower PSA levels, lower Gleason scores, and fewer positive cores and with infiltration by the cancer. 38/42 (91%) of CPC negative men complied with the criteria for active surveillance in comparison with 34/286 (12%) of CPC positive men. Conclusions. Using primary CPC detection as a sequential test to select men with an elevated PSA for biopsy, the risk of missing clinically significant prostate cancer is minimal when the patient is primary CPC negative; less than 0.5% of all primary CPC negative men had a clinically significant prostate cancer.

Highlights

  • Prostate cancer is the second most common cancer and second cause of cancer death in Chilean men [1].Prostate specific antigen (PSA) is the most accurate serum marker for prostate and the only biomarker routinely used for the early detection of prostate cancer

  • Men negative for primary malignant CPC (mCPC) were significantly older and had lower serum PSA levels, lower Gleason scores, lower number of cores positive for prostate cancer, and cores less infiltrated with cancer

  • Comparing men mCPC negative with those mCPC positive using the Epstein criteria [18] for active surveillance, 38/42 (91%) of mCPC negative men compared with 34/286 (12%) (P < 0.0001) of mCPC positive men complied with the criteria for active surveillance of their prostate cancer (Table 2)

Read more

Summary

Introduction

Prostate cancer is the second most common cancer and second cause of cancer death in Chilean men [1].Prostate specific antigen (PSA) is the most accurate serum marker for prostate and the only biomarker routinely used for the early detection of prostate cancer. Approximately 70% of men with an increased serum PSA, defined as >4.0 ng/mL, do not have prostate cancer [4] and undergo unnecessary prostate biopsies. The search for new biomarkers to improve the diagnostic yield is needed This is especially so as Journal of Oncology the risks of prostate biopsy are not insignificant; Rietbergen et al [13], in a study of 5,802 patients undergoing transrectal prostate biopsy, reported an incidence of complications of 0.5% hospitalizations, 2.1% rectal hemorrhage, 2.3% fever, and 7.2% persistent hematuria

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call